Kairos Pharma Ltd.

07/22/2026

announced a strategic collaboration with Bayer to evaluate ENV-105 in combination with XOFIGO for metastatic castration-resistant prostate cancer involving bone.

ENV-105 previously demonstrated an 86% clinical benefit rate in the Company's Phase 2 trial in treatment-resistant mCRPC.

The collaboration will evaluate whether the combination can enhance the activity of XOFIGO.

Read the full announcement: https://bit.ly/4hl7wnq

06/09/2026

Join 's CSO, Neil Bhowmick, at the Technology Network's The Landscape of Cancer Research: Advances in Immuno-Oncology 2026 symposium, taking place June 17-18.

Neil will join fellow researchers and industry leaders to discuss advances in immuno-oncology and the evolving landscape of cancer research.

Learn more and register: https://bit.ly/4e12PMn

06/04/2026

provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu, M.D.

Read the full letter here: bit.ly/43j8sR5

05/05/2026

remains one of the biggest challenges in medicine.

In a new BioSpace article, John Yu, CEO of , explains why it should be treated as a central scientific priority, not an inevitable outcome.

As therapies advance, diseases adapt, limiting long-term effectiveness. Addressing resistance at its core could help extend treatment durability and improve outcomes.

Read more: https://bit.ly/4tI4vkm

We must treat drug resistance as a central scientific priority rather than an unavoidable complication.

04/15/2026

is proud to be recognized as an Emerald Honoree in the Pinnacle Awards for Healthcare for Innovator of Biotech Solutions.

This recognition reflects ’s commitment to advancing innovative cancer therapies, with a focus on addressing drug resistance and improving treatment durability.

We’re grateful for the recognition and encouraged by the continued progress of our team.

Read more: https://bit.ly/3O8mFMR

03/31/2026

Drug resistance remains one of the biggest challenges in cancer treatment.

's CSO, Neil Bhowmick, shares his perspective in this
Drug Target Review article.

Read more: https://bit.ly/4bN3C2h

Explore cancer drug resistance and its significant impact on treatment options and patient outcomes in modern cancer therapy.

03/24/2026

At this year's Deal Flow Discovery Conference, 's Chief Scientific Officer, Neil Bhowmick, discussed the Company’s approach to extending the life of existing cancer therapies.

He shares insights on the potential of ENV105 in castration-resistant , including Phase 2 results showing no Grade 3 or Grade 4 toxicities, as well as early progress in EGFR-driven .

Watch the interview: https://bit.ly/474T25e

In our on-the-ground DealFlow Discovery Conference interview, Dr. Neil Bhowmick, Chief Scientific Officer and President of Kairos Pharma (NYSE American: KAPA...

02/03/2026

is excited to share that Neil Bhowmick, Ph.D., President and Chief Scientific Officer, will be speaking at The Scientist’s upcoming symposium, Emerging Therapeutic Strategies in Oncology, taking place March 17-18, 2026.

The live, on-demand event will bring together leading experts to explore breakthroughs in , targeted treatments, and next-generation cancer therapies shaping the future of .

Register here: https://bit.ly/49MUdYP